Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Shalabh Singhal, Thomas Wegman et al.|Arthritis & Rheumatology|2022

Cited by 246